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Abstract
The aim of this study was to compare the long-term outcome of classic infan-
tile Pompe patients treated with 20 mg/kg alglucosidase alfa every other week
(eow) to those treated with 40 mg/kg/week, and to study the additional effect
of immunomodulation. Six patients received 20 mg/kg eow and twelve 40 mg/
kg/week. Five patients were cross-reactive immunologic material (CRIM)-neg-
ative, two in the 20 mg, three in the 40 mg group. We compared (ventilator-
free) survival, motor outcome, infusion associated reactions (IARs), and anti-
body formation. From 2012 on patients >2 months in the 40 mg group also
received immunomodulation with rituximab, methotrexate, and intravenous
immunoglobulin (IVIG) in an enzyme replacement therapy (ERT)-naïve set-
ting. Survival was 66% in the 20 mg group and 92% in the 40 mg group. Venti-
lator-free survival was 50% and 92%. Both CRIM-negative patients in the
20 mg group died, whereas all three are alive in the 40 mg group. In the 20 mg
group, 67% learned to walk compared with 92% in the 40 mg group. At the age
Abbreviations: AIMS, Alberta Infant Motor Scale; BSID-II, Bayley Scales of Infant Development II; CRIM, cross-reactive immunological material;
ELISA, enzyme-linked immuno sorbent assay; ERT, enzyme replacement therapy; eow, every other week; GAA, acid-α-glucosidase; IAR, infusion
associated reaction; IVIG, intravenous immunoglobulin; LSDs, lysosomal storage disorders; LVMI, left ventricular mass index; rhGAA, recombinant
human GAA.
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of 3 years, 33% and 92% were able to walk. Peak antibody titers ranged from
1:1250 to 1:31 250 in the 20 mg group and from 1:250 to 1:800 000 in the 40 mg
group. Five patients of the 40 mg group of whom two CRIM-negative also
received immunomodulation. B-cell recovery was observed between 5.7 and
7.9 months after the last dose of rituximab. After B-cell recovery titers of
patients with and without immunomodulation were similar (ranges 1:6 250-
1:800 000 and 1:250-1:781 250). This study shows that classic infantile patients
treated with 40 mg/kg/week from the start to end have a better (ventilator-free)
survival and motor outcome. Immunomodulation did not prevent antibody for-
mation in our study.
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1 | INTRODUCTION
Intravenous enzyme replacement therapy (ERT) with
recombinant human enzymes is the treatment of choice
for several lysosomal storage disorders (LSDs).1 Among
them is Pompe disease (glycogen storage disease type II,
OMIM: #232300), an autosomal recessive LSD caused by
deficiency of the enzyme acid-α-glucosidase (GAA).2,3
The disease spectrum is broad. The most severe classic
infantile form presents shortly after birth with a hyper-
trophic cardiomyopathy and generalized muscle weak-
ness. Without therapy patients die within the first year of
life.4,5 Major motor milestones like walking are not
achieved, GAA deficiency is profound (<1%) and the
GAA variants are very severe.3,6,7 One-third of the
patients are cross-reactive immunologic material (CRIM)
negative and do not produce any alpha-glucosidase pro-
tein. The alpha-glucosidase protein produced by CRIM-
positive patients is not adequately transported to the lyso-
somes and inactive. The registered dose of recombinant
human GAA (rhGAA, alglucosidase alfa) for all patients
is 20 mg/kg every other week (eow).2,3 This dose is
mainly based on the results of the initial pivotal clinical
trial (AGLU 01602) in which patients received either 20
or 40 mg/kg eow.8 This trial in 18 classic infantile
patients lasted 52 weeks and all survived beyond the first
year of life. There was no clear difference between the
outcomes of the 20 or 40 mg/kg eow group. A longer fol-
low-up study showed that there is still room for improve-
ment as nearly 50% of patients did not survive ventilator-
free beyond the age of 3 years and 56% did not learn to
walk.8,9 More recent longer follow-up studies report simi-
lar results.10-12
Clinical and preclinical studies have shown that skel-
etal muscles are difficult to target and that uptake is dose
dependent.13-17 Other factors that have shown to be of
influence on outcome are CRIM status and antibody for-
mation.18-20 CRIM-negative patients have shown to per-
form poorly and tend to produce high anti-rhGAA
antibody titers. The outcome of CRIM-positive patients
seems more variable. In these patients, high sustained
titers have also been reported to have a negative
effect.18,19,21-23
To improve clinical outcomes, we have investigated
the effect of a higher dose of 40 mg/kg/week. This dose
was applied in our very first clinical trial with recombi-
nant human alpha-glucosidase produced in milk from
transgenic rabbits in 1999. This study showed that
enzyme activity levels in skeletal muscle were higher
with a dose of 40 mg/kg/week than with 15 or 20 mg/kg/
week.15 From 2009 onwards, all our newly diagnosed
patients received 40 mg/kg/week from the start. In 2016,
we published our preliminary results in eight CRIM-posi-
tive patients comparing 20 mg/kg eow with 40 mg/kg/
week.20 Here, we present our longer follow-up data in a
larger cohort of 18 patients also including CRIM-negative
patients. From 2012 onwards, we further investigated
whether immunomodulation, using a protocol published
by Messinger et al,24,25 aimed to prevent the production
of anti-rhGAA antibodies, in combination with a higher
dose had added benefit.
2 | METHODS
2.1 | Patients and treatment
In this prospective standardized follow-up study, all
Dutch patients diagnosed with classic infantile Pompe
disease who were treated with rhGAA (Alglucosidase
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alfa, Myozyme) from the start were included. The Pompe
Center at Erasmus MC is the single reference center for
ERT of Pompe patients in the Netherlands. Classic infan-
tile Pompe disease was defined as (a) symptoms of mus-
cle weakness within 6 months after birth, (b) the
presence of hypertrophic cardiomyopathy, (c) deficiency
of endogenous α-glucosidase in fibroblasts (<1% of the
normal values), and (d) pathogenic variants in the GAA
gene.3 ERT was dosed at 20 mg/kg eow between 2003
and 2009. From 2009 onwards, all newly diagnosed
patients received 40 mg/kg/week. Dosing of all patients
receiving 20 mg/kg eow was increased to 40 mg/kg/week
somewhere between 2009 and 2014, due to clinical deteri-
oration. In 2012, immunomodulation with rituximab
(RTX), methotrexate (MTX) and intravenous immuno-
globulins (IVIG) in an ERT-naïve setting was initiated in
newly diagnosed patients older than 2 months of age at
the time of diagnosis (see for details25). Antibiotic pro-
phylaxis was given to prevent (respiratory) infections.
Data until December 31st 2016 were analyzed.
2.2 | Clinical efficacy
Standardized assessments were performed at baseline and
every 3 months thereafter.16,20 Study protocols were
approved by the Institutional Review Board and written
informed consent was obtained from the parents and/or
patients. Clinical outcome was assessed by (ventilator-free)
survival. Cardiac dimensions were measured by conventional
echocardiography; the left ventricular mass index (LVMI)
was calculated by the Devereux formula and indexed by
body surface area. An LVMI of > +2 SD of age-related peers
was considered abnormal.26 Motor function was assessed by
Alberta Infant Motor Scale (AIMS) and Bayley Scales of
Infant Development II (BSID-II), and motor milestones were
recorded.27,28 Results were compared to age-related healthy
peers. Infusion associated reactions (IARs) were noted when
they occurred. The severity of each IAR was indexed by clini-
cal judgment as mild/moderate or severe.
2.3 | Antibody detection
Anti-rhGAA titers were assessed at the start of ERT and
thereafter at 3, 6, 9, 12, 18, 24 months and from then on
yearly. When receiving immunomodulation, titers were also
determined at 1 and 2 months after the start.25 Standardized
antibody analysis was performed by an enzyme-linked
immunosorbent assay (ELISA) as previously described.19,22,29
Antibody titers were measured in 5-fold serial dilutions. Sam-
ples were measured in duplicate. Assays were performed at
least twice. The background of the ELISA method was
determined to be 1:250 by omitting the coating of the plates
with rhGAA as described previously.22
3 | RESULTS
3.1 | Patients
Eighteen patients were included, nine (50%) were male.
Table 1 compares the patient groups treated with 20 mg/kg
eow (n = 6) and 40 mg/kg/week (n = 12). Age at start of
treatment was younger in the 20 mg group and ranged from
0.1 to 3.6 months (median 1.5 months) compared to 0.3 to
5.9 months (median 3.6 months) in the 40 mg group. Two
patients in the 20 mg group were CRIM-negative and three
in the 40 mg group. Age at the last assessment ranged from
0.6 to 12.6 years (median 9.6 years) and from 3.0 to
8.3 years (median 4.4 years) for both groups. Four patients
treated with 20 mg/kg eow had their dose increased to
40 mg/kg/week at ages ranging from 1.5 to 9.4 years either
because of serious respiratory infections, becoming ventila-
tor dependent or motor decline. Figure S1 shows the treat-
ment regimen per patient.
3.2 | Effects of higher dosing on clinical
outcomes
At the study end, survival was 66% in the 20 mg group
and 92% in the 40 mg group (P = .25). (Figure 1). Three
patients died (aged 0.6, 3.1, and 4.4 years) due to respira-
tory failure; both CRIM-negative patients from the 20 mg
group and one CRIM-positive patient from the 40 mg
group. Ventilator-free survival was 50% for the 20 mg
group and 92% for the 40 mg group (P = .08).
The ability to walk was achieved by four patients (67%)
in the 20 mg group and by 11 (92%) in the 40 mg group. By
the age of 3 years, two (33%) in the 20 mg group and 11
(92%) patients in the 40 mg group maintained the ability to
walk (P = .02). At the end of the study, respectively, one
(17%) and 10 (83%) were persistent walkers.
Figure 1 and Table 1 show the AIMS and BSID-II
scores per treatment group. Although the ranges in AIMS
and BSID-II scores were similar, only patients from the
40 mg group (n = 6 of whom two were CRIM-negative)
reached the maximum AIMS score of 58. The median
BSID-II age-equivalent score at 36 months was higher for
the 40 mg group, 30 months, compared to 20 months for
the 20 mg group. Only 50% of patients in the 20 mg group
compared to 92% of patients in the 40 mg group could be
adequately tested with the BSID-II at 36 months. The test
was not performed in the others either because they had
died (n = 3) or were ventilator-dependent (n = 1).
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TABLE 1 Patient characteristics and outcome comparing 20 mg/kg eow with 40 mg/kg/week
20 mg/kg eow 40 mg/kg/week
Patient characteristics
Number of patients 6 12
Males (%) 4 (67%) 5 (42%)
Median age at start in months (range) 1.5 (0.1-3.6) 3.6 (0.3-5.9)
Number of CRIM-negative (%) 2 (33%) 3 (25%)
ERT dose increase 4 (67%)a N.A.
Age at dose increase in years (median, range) 4.1 (1.5-9.4) N.A.
Outcome
Median age at last assessment in years (range) 9.6 (0.6–12.6) 4.4 (3.0-8.3)
Survival (%) 66% 92%
Survival of CRIM-negative patients (%) 0% 100%
Ventilator-free survival (%) 50% 92%
Median LVMI z-score at start (range) 6.15 (2.4-8.6) 7.1 (3.0-13.7)
Number of patients with LVMI normalization during follow-up (%) 5 (83%) 11 (92%)
Median ERT duration at LVMI normalization in years (range) 0.5 (0.25-1.71) 0.5 (0.25-1.4)
Best motor milestone (%)
MMF 1 (17%) 0
Sitting 1 (17%) 1 (8%)
Walking 4 (67%) 11 (92%)
Number of patients walking independently at age 3 years (%) 2 (33%) 11 (92%)
Last motor milestone (number, %)
MMF 1 (17%) 0
Sitting 4 (67%) 2 (17%)
Walking 1 (17%) 10 (83%)
AIMS at 12 months (median, range) 37 (20-45)b 39 (20-50)
AIMS at 18 months (median, range) 54 (25-57)b 57 (34-58)
BSID-II AE score at 24 months (median, range) 17 (10.4-21)c 18 (14-25)
BSID-II AE score at 36 months (median, range) 20 (20-32)c 30 (19-33)d
Median peak antibody titer (range) 1:6250 (1250-31 250) 1:156250 (250-800 000)
Tube feeding at start (number, %)
NGT 6 (100%) 9 (75%)
PEG 0 0
Oral 0 3 (25%)
Tube feeding at study end (number, %)
NGT 1 (17%) 1 (8.5%)
PEG 2 (33%) 1 (8.5%)
Oral 3 (50%) 10 (83%)
Number of patients with IARs (total number of IARs) 5 (64 IARS, 4 severe) 8 (134 IARS, 11 severe)
Abbreviations: AIMS, Alberta Infant Motor Scale; BSID-II AE; Bayley Scales of Infant Development II age-equivalent score; CRIM, cross-
reactive immunological material; ERT, enzyme replacement therapy; IARs, infusion associated reactions; LVMI, left ventricular mass index;
MMF, minimal motor function; NGT, nasogastric tube; PEG, percutaneous endoscopic gastrostomy.
aDose increase was only applied in the surviving four patients from the 20 mg group.
bAIMS at 12 and 18 months was performed in the five surviving patients.
cBSID-II was performed in three patients, the two patients requiring invasive ventilation were not tested due to illness.
dBSID-II at 36 months was performed in the surviving 11 patients, two patients were 34 months of age at time of testing.
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The cardiac response, effect on LVMI, did not show
considerable differences between the two groups (Figure S2).
The LVMI did not normalize in one patient who died after
3 months of treatment (20 mg group). Two patients in
40 mg group had a severe dilated cardiomyopathy at start,
which responded well to treatment. In one of those patients,
LVMI was still slightly elevated at the last assessment
+2.1 SD (+13.7 SD at start).
3.3 | Additional effect of
immunomodulation in patients receiving
40 mg/kg/week
Five of 12 patients in the 40 mg group received additional
primary immunomodulation (immunomodulation in an
ERT-naïve setting) with rituximab, methotrexate, and
IVIG. This protocol was introduced in 2012 in patients
older than 2 months of age to prevent antibody formation
and to further improve outcomes. Start ERT ranged from
0.1 to 3.6 months in the 20 mg group and from 0.3 to
5.9 months in the 40 mg group. We first compared the
clinical outcome of patients treated with 40 mg/kg/week
monotherapy (40 mg mono group, n = 7, CRIM-negative
1) and those treated with 40 mg/kg/week plus immuno-
modulation (40 mg immuno group, n = 5, CRIM-negative 2,
Table 2). The 40 mg immuno group was slightly older
(range 3.1-5.8 months) compared to the 40 mg mono
group (range 0.3-4.8 months) at start.
At the end of the study, (ventilator-free) survival was
86% (six of seven) in the 40 mg mono group and 100% (five
of five) in the 40 mg immuno group (Table 2). The patient
who died was CRIM-positive. The ability to walk was
achieved by six of seven patients (86%) in the 40 mg mono
group and by five (100%) in the 40 mg immuno group. All
patients were still able to walk at the age of 3 years. At the
FIGURE 1 Survival and motor outcome. A, Survival in patients receiving 20 mg/kg ERT eow and B, 40 mg/kg/week. Gray lines represent
the historical cohorts. C, AIMS score in patients receiving 20 mg/kg eow and D, 40 mg/kg/week. E, BSID-II score in patients receiving 20 mg/kg/
eow and F, 40 mg/kg/week. In the right part of the panel data, patients treated with 40 mg/kg/week were subdivided in outcomes for patients
receiving 40 mg/kg/week ERT monotherapy and patients receiving 40 mg/kg/week ERT with immunomodulation. B1-B2, Survival; D1-D2, AIMS
score; F1-F2, BSID-II score. Dashed lines in C-F represent the deceased patients. The asterisks mark the patients who required invasive ventilation.
AIMS, Alberta Infant Motor Scale; BSID-II, Bayley Scales of Infant Development II; ERT, enzyme replacement therapy
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TABLE 2 Patient characteristics and outcome comparing 40 mg/kg/week monotherapy to 40 mg/kg/week with immunomodulation
40 mg/kg/week monotherapy 40 mg/kg/week immunomodulation
Patient characteristics
Number of patients 7 5
Males (%) 3 (43%) 2 (40%)
Median age at start in months (range) 3.1 (0.3-4.8) 4.3 (3.1-5.8)
Number of CRIM-negative (%) 1 (14%) 2 (40%)
Outcome
Age at last assessment in years (median, range) 6.0 (3.1-8.3) 3.8 (3.0-4.8)
Survival (%) 86% 100%
Ventilator-free survival (%) 86% 100%
Median LVMI z-score at start (range) 7.0 (3.0-9.6) 7.8 (4.0-13.7)
Number of patients with LVMI normalization during
follow-up (%)
7 (100%) 4 (80%)
Median ERT duration at LVMI normalization in years
(range)
0.9 (0.25-0.75) 0.5 (0.25-1.4)
Best motor milestone (number, %)
MMF 0 0
Sitting 1 (14%) 0
Walking 6 (86%) 5 (100%)
Number of patients walking independently at age
3 years (%)
6 (86%) 5 (100%)
Last motor milestone (number, %)
MMF 0 0
Sitting 2 (29%) 0
Walking 5 (71%) 5 (100%)
AIMS at 12 months (median, range) 41.5 (27-50) 36 (20-49)
AIMS at 18 months (median, range) 58 (34–58) 56 (35-58)
BSID-II AE score at 24 months (median, range) 18 (14-25) 18 (15-19)
BSID-II AE score at 36 months (median, range) 31 (30-33) 23 (19-31)
Peak antibody titer (median, range) 1:156 250 (250-781 250) 1:468750 (6250-800 000)
Antibody titer at last assessment (median, range) 1:31 250 (250-781 250) 1:93750 (250-781 250)
Tube feeding at start (number, %)
NGT 4 (57%) 5 (100%)
PEG 0 0
Oral 3 (43%) 0
Tube feeding at study end (number, %)
NGT 1 (14%) 0
PEG 1 (14%) 0
Oral 5 (71%) 5 (100%)
IARs in number of patients (total number of IARs) 6 (110 IARS, 6 severe) 2 (24 IARs, 5 severe)
Abbreviations: AIMS, Alberta infant motor scale; BSID-II AE; Bayley Scales of Infant Development II age-equivalent score; CRIM, cross-
reactive immunological material; ERT, enzyme replacement therapy; IARs, infusion associated reactions; LVMI, left ventricular mass index;
MMF, minimal motor function NGT, nasogastric tube; PEG, Percutaneous endoscopic gastrostomy.
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end of the study, five (71%) in the 40 mg mono group and
five (100%) in the 40 mg immuno group were persistent
walkers, including all three CRIM-negative patients. The
age range of patients at the last assessment was 3.1 to 8.3
(median 6.0) years for 40 mg mono group and 3.0 to 4.8
(median 3.8) years for the 40 mg immuno group. Figure 1
and Table 2 show the AIMS and BSID-II scores per treat-
ment group. The ranges in AIMS and BSID-II scores were
similar. Also, response on LVMI was similar.
3.4 | Anti-rhGAA antibody titers
and IARs
When comparing antibody titers between the 20 mg and
the combined 40 mg groups peak titers ranged from
1:1250 to 1:31 250 in the 20 mg group (median 1:6250)
and from 1:250 to 1:800 000 (median 1:156 250) in the
40 mg group. Two patients in 20 mg group developed
high (sustained) titers of 1:31 500 (one was CRIM-negative),
and seven in the 40 mg group (see for details below).
Figure 2 shows anti-rhGAA antibody titers during
follow-up per patient.
Immunomodulation resulted in B-cell depletion in all
patients receiving immunomodulation. B-cell recovery
was observed between 5.7 and 7.9 months after the last
dose of rituximab.25
Comparison between the 40 mg mono and the 40 mg
immuno groups showed peak titers ranging from 1:250 to
1:78 1250 (median 1:156 250) for the 40 mg mono group
and titers ranging from 1:6250 to 1:800 000 (median
1:468 750) for 40 mg immuno group. All CRIM-negative
patients in 40 mg group developed high sustained titers
irrespective of whether they received immuno-
modulation; four of the nine CRIM-positive patients
developed high sustained titers, one had received primary
immunomodulation.
IARs were observed in all groups. Five patients (83%)
in the 20 mg group and eight (67%) in the 40 mg group
experienced IARs. Comparison between 40 mg mono and
40 mg immuno groups revealed that six (86%, CRIM-positive
and CRIM-negative) and two (40%, CRIM-negative) patients
experienced IARs, respectively. In all, but two patients
(both CRIM-negative), IARs were treated successfully
and had not reoccurred for at least 12 months.
4 | DISCUSSION
The primary aim of this study was to investigate the role
of higher ERT dosing on clinical outcomes. ERT has gen-
erally improved short-term survival of patients, but with
longer follow-up it has become evident that there are still
FIGURE 2 Anti-rhGAA antibody titers in patients receiving
20 mg/kg ERT eow compared to 40 mg/kg/week monotherapy and
40 mg/kg/week and immunomodulation. Each line represents an
individual patient. Dashed lines indicate the CRIM-negative
patients per group. A, Anti-rhGAA antibody titers in patients
receiving 20 mg/kg eow; B, Anti-rhGAA antibody titers in patients
receiving 40 mg/kg/week monotherapy. C, Anti-rhGAA antibody
titers in patients receiving 40 mg/kg/week and immunomodulation
in an ERT-naïve setting. CRIM, cross-reactive immunological
material; ERT, enzyme replacement therapy; rhGAA, Recombinant
human acid-α-glucosidase
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considerable unmet clinical needs as 50% of the reported
patients do not survive ventilator-free at the age of
3 years and even lower numbers obtain or maintain the
ability to walk.8,9 The current study shows that classic
infantile patients receiving an ERT dose of 40 mg/kg/
week from start tend to have a better survival and venti-
lator-free survival (92% for both outcomes) than patients
who started on 20 mg/kg eow (66% and 50%). They also
tend to have a better motor outcome: 92% achieved the
ability to walk and 83% are still able to walk at study end
(median age 4.4 years, range 3.0-8.3 years), compared to
67% and 17%, respectively, in the 20 mg group (median
age 9.6 years, range 0.6-12.6 years). At the age of 3 years,
92% and 33% were able to walk. The latter effect was sig-
nificant. Most notable was that all three CRIM-negative
patients in the 40 mg group were alive at study end and
able to walk compared to none in 20 mg group. Five
patients of the 40 mg group (of whom two of the three
CRIM-negative) also received immunomodulation in an
ERT-naïve setting. Immunomodulation did not prevent
antibody formation in our study. All patients receiving
immunomodulation were alive and persistent walkers at
the end of the study.
Studies from various countries have reported the
long-term outcome of patients with classic infantile
Pompe disease: the UK, Germany, and Italy, and the ini-
tial pivotal trial (AGLU 01602).8-12 Most of the patients
(n = 102) in these combined studies started ERT on
20 mg/kg eow. The maximum follow-up of patients in
these studies ranged from 3 to 13.6 years. The median fol-
low-up duration of the 01602 extension study was the
shortest (2.3 years). Reported survival ranged from 56%
to 66% and ventilator-free survival was 29% to 50% in the
various studies. The ability to walk was achieved in 25%
to 44%, and 19% to 39% of patients were persistent
walkers at study end. The maximum follow-up in our
study was 12.6 years for the 20 mg group and 8.3 years
for the 40 mg group. The clinical results of our 20 mg
group are similar to the results published in literature
(67% for survival, 50% for ventilator-free survival, 67%
walkers and 17% persistent walkers). In our study, the
surviving four patients of the 20 mg group were all
increased in dose to 40 mg/kg/week at ages ranging from
1.5 to 9.4 years because of clinical deterioration. Khan et
al recently also reported that a standard dose of 20 mg/kg
eow is insufficient to halt progression of disease and that
40 mg/kg/week should be considered in patients with
clinical and functional decline.30 Unfortunately, in our
study, dose increase after deterioration could not prevent
that only one is a persistent walker.
A potential explanation for the better outcome in the
40 mg group is that a higher dose is required to obtain
sufficient uptake by muscle cells and transport of rhGAA
to the lysosomes, and a more frequent dose to maintain
a sufficient GAA activity level in the lysosomes for gly-
cogen clearance.13,17 The estimated intracellular half-life
of GAA after uptake based on preclinical studies is 3 to
7 days. Fourteen days between infusions may be too
long. It should be noted that ERT in other LSDs, such as
MPS I, II, IV, and VI are also administered weekly.1 This
could explain why in the AGLU 01602 trial no obvious
clinical benefit of 40 mg/kg eow over 20 mg/kg eow was
observed.8,9 It was further noted by the authors of the
AGLU 01602 trial that there was an over-representation
of CRIM-negative patients receiving 40 mg/kg eow that
may have also contributed to the limited effect. A recent
study of Spada et al also suggested that weekly higher
dosing from start might lead to a better outcome.31
Regarding antibodies, we found anti-rhGAA antibody
titers in both groups. High sustained antibody titers of
≥1:31 500 developed in four of the nine CRIM-positive
and all three CRIM-negative patients in the 40 mg group
and in one CRIM-positive patient in the 20 mg group.
This might indicate that antibody titers were generally
higher in the higher dose group, but it should also be
noted that these patients were generally older at start.
Earlier, we observed that patients who started ERT
within the first 2 months of life seemed to develop lower
titers than those who started ERT later.19,20 Figure S3
shows antibody titers in patients who started ERT before
and after 2 months of age and might point in the same
direction. Further research is needed. Regarding the
inhibitory effect of antibody titers, we previously found
that patients with titers <1:31 250 did not show inhibi-
tory effects of anti-rhGAA antibody titers in enzyme
uptake experiments and immunoprecipitation19 and cal-
culated that in a patient with a titer of 1:156 250, with a
blood volume of 80 mL/kg and an ERT dose of 20 mg/kg,
54% of the infused enzyme (about 10 mg/kg) could possi-
bly be bound to antibodies.19,29 Theoretically, with a
higher dose more antibody-free rhGAA will be available
and the anticipated neutralizing effects of antibodies less
severe. This may explain why we observed a good clinical
outcome in most of our patients despite high titers and
why all our CRIM-negative patients in 40 mg group are
currently alive and persistent walkers, where other stud-
ies rarely report survival in CRIM-negative patients.
The second aim was to investigate whether immuno-
modulation could further improve clinical outcomes. In
patients receiving immunomodulation in an ERT-naïve
setting in combination with a high dose we achieved
100% ventilator-free survival and all are persistent
walkers. It should be noted that this group of patients
was the youngest of the groups that we compared with
the shortest follow-up. Immunomodulation has become a
major focus in the treatment of classic infantile Pompe
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patients to improve clinical outcomes.10,24,25,32-34 We
applied immunomodulation protocols in an ERT-naïve
setting similar to what was reported in literature.24,25 The
effect of our immunomodulation regimen on the anti-
body titers was limited. There are several reports that
were successful in eliminating and/or preventing anti-
body formation. In Reference [25], we reviewed results
and the regimens applied to 24 patients receiving immu-
nomodulation in an ERT-naïve setting reported in the lit-
erature. The age range of these patients at the last
assessment was 4 to 49 months. At the time of the report,
19 of 24 were alive (survival 79%) and 17 of 24 (71%) sur-
vived ventilator free. Thirteen of the 24 patients were
older than 18 months at time of report; six of these 13
patients learned to walk (46%); five of these (38%) were
persistent walkers. Only two patients were 3 years or
older (36 and 49 months). Both patients did not achieve
the ability to walk (see Reference [25] for review).
Most of these patients were CRIM-negative and all
patients started ERT on 20 mg/kg eow, yet some were
receiving a higher dose at study end. This shows that
standard dose in combination with immunomodulation
not always leads to a good outcome. Kazi et al reported
on 19 CRIM negative patients, age at study end was 7.1
to 103.9 months (median 30.1) who received immuno-
modulation in an ERT naïve setting. Survival in this
group was 73% (14 of 19), 36% (7 of 19) was ambulatory
and 36% (7 of 19) were ventilator free at last assessment.
In this study, the dose varied.36
We hypothesize that in our study a higher more fre-
quent ERT dose is the main reason for the good clinical
outcome. Immunomodulation may have contributed to
the clinical stability of our patients, but it did not prevent
antibody formation in our study. It should be noted how-
ever that the higher dose cannot overcome all limitations.
Many patients in the 40 mg group still have residual mus-
cle weakness and some also lose motor milestones. Thus,
the road to a cure for classic infantile patients does not
end here. This also includes the implementation of suc-
cessful immunomodulatory regimens to prevent or
reduce high antibody titers, which we also consider of
utmost importance.
It should be noted that our study had several limitations.
Although the number of classic infantile patients is relatively
large, the absolute number and numbers of subjects in the
subgroups are still small. Findings have to be interpreted
cautiously. Due to small sample size statistics could only be
applied for a limited number of outcome measures.
Finally, we found high sustained antibody titers and
IARs in both dose groups, in both CRIM-positive and
CRIM-negative patients. The relationship between the
antibody titers and IARs is very complex and warrants
further investigation.
In conclusion, the present study shows that our classic
infantile patients receiving 40 mg/kg/week from start
have a better survival, ventilator-free survival and motor
outcome than patients receiving 20 mg/kg eow. Most
notable, all three CRIM-negative patients in the 40 mg
group were alive and able to walk at study end
irrespective of whether they received immunomodulation.
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